First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study
The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not… Read More »First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study